Building An Integrated Neurodegenerative Disease Database At An Academic Health Center

Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Alzheimer's & dementia: the journal of the Alzheimer's Association (Impact Factor: 17.47). 07/2011; 7(4):e84-93. DOI: 10.1016/j.jalz.2010.08.233
Source: PubMed

ABSTRACT It is becoming increasingly important to study common and distinct etiologies, clinical and pathological features, and mechanisms related to neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. These comparative studies rely on powerful database tools to quickly generate data sets that match diverse and complementary criteria set by them.
In this article, we present a novel integrated neurodegenerative disease (INDD) database, which was developed at the University of Pennsylvania (Penn) with the help of a consortium of Penn investigators. Because the work of these investigators are based on Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration, it allowed us to achieve the goal of developing an INDD database for these major neurodegenerative disorders. We used the Microsoft SQL server as a platform, with built-in "backwards" functionality to provide Access as a frontend client to interface with the database. We used PHP Hypertext Preprocessor to create the "frontend" web interface and then used a master lookup table to integrate individual neurodegenerative disease databases. We also present methods of data entry, database security, database backups, and database audit trails for this INDD database.
Using the INDD database, we compared the results of a biomarker study with those using an alternative approach by querying individual databases separately.
We have demonstrated that the Penn INDD database has the ability to query multiple database tables from a single console with high accuracy and reliability. The INDD database provides a powerful tool for generating data sets in comparative studies on several neurodegenerative diseases.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Rationale and Objectives: The objective of this study was to demonstrate that an intra-arterial liver therapy clinical research database system is a more workflow efficient and robust tool for clinical research than a spreadsheet storage system. The database system could be used to generate clinical research study populations easily with custom search and retrieval criteria. Materials and Methods: A questionnaire was designed and distributed to 21 board-certified radiologists to assess current data stor-age problems and clinician reception to a database management system. Based on the questionnaire findings, a customized data-base and user interface system were created to perform automatic calculations of clinical scores including staging systems such as the Child-Pugh and Barcelona Clinic Liver Cancer, and facilitates data input and output. Results: Questionnaire participants were favorable to a database system. The interface retrieved study-relevant data accurately and effectively. The database effectively produced easy-to-read study-specific patient populations with custom-defined inclusion/exclu-sion criteria. Conclusions: The database management system is workflow efficient and robust in retrieving, storing, and analyzing data. W ith the growing amount of clinical research studies in the field of interventional oncology, selective patient data are becoming more difficult to store and organize effectively. Existing hospital electronic medical record (EMR) systems store patient data in the form of reports and data tables. Our institution's EMR system placed our researchers in a position where time-consuming methods are needed to search for suitable patients for clinical studies. Researchers had to manually read through the reports and data tables to filter patients and gather data. For most studies, spreadsheet programs such as Microsoft Excel (Microsoft, Washington) are often used as a data repository similar to a database to record and organize patient data for research. Once the spreadsheet is populated, it is manually filtered by set study parameters and then pushed to statistical analysis software for further analysis. For statistical analysis, columns containing text are translated into binary values (1 or 0) to be in a format acceptable by statistical analysis software. For example, each tumor entity is assigned a new column. Patient histologic reports are read manually to assign a value of 1 or 0 to each tumor entity column, 1 for positive, and 0 for nega-tive. Under a tumor entity column, researchers would write a value of 1 for all patients with the tumor and a 0 for all patients without the tumor. This method of data storage has limitations in the organiza-tion and the quality of the data. Data input and analysis without a database run a higher risk of incorrect data entry, patient exclusion, and a higher risk of introducing duplicates. Further-more, data selection and calculation are time consuming. An alternative could be the clinical research database that Meineke et al. proposed (1). However, it is too unspecific for interven-tional oncology research and would need additional optimiza-tion, for example, the capability to automatically calculate various variables such as tumor staging systems and to record information about multiple treatment sessions. The purpose of this study was to provide an improved workflow-efficient tool through the use of a clinical research database management system (DBMS) optimized for inter-ventional oncology clinical research.
    Academic radiology 01/2015; 26(2). DOI:10.1016/j.acra.2014.12.002 · 2.08 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: An histone deacetylase (HDAC) inhibitor database (HDACiDB) was constructed to enable rapid access to data relevant to the development of epigenetic modulators (HDAC inhibitors [HDACi]), helping bring precision cancer medicine a step closer. Thousands of HDACi targeting HDACs are in various stages of development and are being tested in clinical trials as monotherapy and in combination with other cancer agents. Despite the abundance of HDACi, information resources are limited. Tools for in silico experiments on specific HDACi prediction, for designing and analyzing the generated data, as well as custom-made specific tools and interactive databases, are needed. We have developed an HDACiDB that is a composite collection of HDACi and currently comprises 1,445 chemical compounds, including 419 natural and 1,026 synthetic ones having the potential to inhibit histone deacetylation. Most importantly, it will allow application of Lipinski's rule of five drug-likeness and other physicochemical property-based screening of the inhibitors. It also provides easy access to information on their source of origin, molecular properties, drug likeness, as well as bioavailability with relevant references cited. Being the first comprehensive database on HDACi that contains all known natural and synthetic HDACi, the HDACiDB may help to improve our knowledge concerning the mechanisms of actions of available HDACi and enable us to selectively target individual HDAC isoforms and establish a new paradigm for intelligent epigenetic cancer drug design. The database is freely available on the website.
    Drug Design, Development and Therapy 04/2015; 20159:2257-2264. DOI:10.2147/DDDT.S78276 · 3.03 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective To see whether the distribution patterns of phosphorylated 43kDa TAR DNA-binding protein (pTDP-43) intraneuronal inclusions in amyotrophic lateral sclerosis (ALS) permit recognition of neuropathological stages. MethodspTDP-43 immunohistochemistry was performed on 70m sections from ALS autopsy cases (N = 76) classified by clinical phenotype and genetic background. ResultsALS cases with the lowest burden of pTDP-43 pathology were characterized by lesions in the agranular motor cortex, brainstem motor nuclei of cranial nerves V, VII, and X-XII, and spinal cord -motoneurons (stage 1). Increasing burdens of pathology showed involvement of the prefrontal neocortex (middle frontal gyrus), brainstem reticular formation, precerebellar nuclei, and the red nucleus (stage 2). In stage 3, pTDP-43 pathology involved the prefrontal (gyrus rectus and orbital gyri) and then postcentral neocortex and striatum. Cases with the greatest burden of pTDP-43 lesions showed pTDP-43 inclusions in anteromedial portions of the temporal lobe, including the hippocampus (stage 4). At all stages, these lesions were accompanied by pTDP-43 oligodendroglial aggregates. Ten cases with C9orf72 repeat expansion displayed the same sequential spreading pattern as nonexpansion cases but a greater regional burden of lesions, indicating a more fulminant dissemination of pTDP-43 pathology. InterpretationpTDP-43 pathology in ALS possibly disseminates in a sequential pattern that permits recognition of 4 neuropathological stages consistent with the hypothesis that pTDP-43 pathology is propagated along axonal pathways. Moreover, the finding that pTDP-43 pathology develops in the prefrontal cortex as part of an ongoing disease process could account for the development of executive cognitive deficits in ALS. Ann Neurol 2013;74:20-38
    Annals of Neurology 07/2013; 74(1). DOI:10.1002/ana.23937 · 11.91 Impact Factor


Available from